Healthcare organizations invest significant resources in maintaining sterile compounding environments, yet one of the most underutilized strategies for reducing contamination risk may already exist within their walls: stronger collaboration between pharmacy and infection prevention.
Historically, sterile compounding and infection prevention and control (IPC) teams have operated in silos. Pharmacy teams focus on compliance with USP standards, aseptic technique, environmental controls, and medication preparation, while infection preventionists (IPs) promote a culture of safety for patients and staff. IPs perform surveillance to identify healthcare-associated infections, lead process improvement, guide outbreak response, and promote evidence-based safety policies and practices. Although their daily responsibilities differ, both groups share a common objective—protecting patients from preventable harm.
As healthcare regulations evolve and compounding environments become increasingly complex, organizations have an opportunity to bridge these disciplines in ways that improve risk assessment, strengthen compliance efforts, and enhance patient safety. To address this gap, Karen Jones and Christina Martin hosted a webinar on strengthening partnerships between your pharmacy compounding and infection prevention teams. The discussion revealed five important opportunities to enhance cleanroom safety.
Different perspectives, a shared approach to safer sterile compounding
The revised USP <797> chapter effective November 1, 2023, places significant emphasis on personnel competency, environmental monitoring, cleaning and disinfection programs, facility design, and ongoing quality management. Yet many of these activities also fall within the expertise of infection prevention programs.
Pharmacy professionals are experts in compounding operations, product preparation, workflow design, and USP compliance. Infection preventionists bring a different lens—evaluating infection risks, interpreting microbiological trends, conducting investigations, and developing mitigation strategies.
When those perspectives are combined, organizations gain a more comprehensive approach to cleanroom safety.
1. Identify infection control standards for sterile compounding early in cleanroom design and renovation
Few decisions have a greater long-term impact on contamination control than facility design.
Whether constructing a new cleanroom suite, renovating existing sterile compounding space, or addressing infrastructure concerns, pharmacy and infection prevention should be involved from the earliest planning stages. Pharmacy professionals understand operational workflows and compounding requirements, while infection preventionists bring expertise in environmental controls and infection risk mitigation.
Construction projects also introduce new contamination risks. IPs routinely use Infection Control Risk Assessments (ICRAs) to evaluate risks associated with construction activities and determine appropriate containment strategies. Early collaboration helps organizations identify vulnerabilities before they impact operations.
The most successful projects don't simply meet engineering specifications but also incorporate designs with contamination prevention in mind from day one.
2. Partner on training, hand hygiene, and aseptic practices
People remain the greatest source of contamination within controlled environments.
USP <797> emphasizes hand hygiene, garbing, competency assessments, and aseptic technique for anyone entering sterile compounding spaces. Any person who enters the cleanroom-controlled environment setting, including pharmacy personnel, maintenance staff, contractors, auditors, and visitors, all contribute to potential contamination risk. This creates a valuable opportunity for IPs to support pharmacy training programs.
Organizations that engage IPC teams in competency evaluations, observation audits, and remediation efforts may uncover opportunities for improvement that internal teams overlook. An external observer often identifies workflow deviations, hand hygiene lapses, or garbing inconsistencies that can become normalized over time.
Because IPs routinely evaluate healthcare personnel compliance across clinical environments, they can provide practical coaching and objective feedback that strengthens sterile compounding practices.
3. Move beyond compliance and focus on infection risk
USP standards establish minimum requirements. However, not every compliance deviation carries the same clinical risk.
One of the most valuable contributions IPs can make is helping pharmacy teams interpret findings through a patient-safety lens. While USP <797> describes monitoring frequencies, action levels, and operational requirements, it may not always provide detailed guidance on the true infection risk associated with specific contamination events.
For example, environmental monitoring programs frequently detect microorganisms that require investigation. Pharmacy teams may accurately identify a recovery event, yet questions often remain, such as:
- Is the organism clinically significant?
- Has it been recovered elsewhere in the facility?
- Does it pose an elevated risk to immunocompromised patients?
- Does the finding warrant enhanced surveillance or operational restrictions?
These questions extend beyond USP compliance and often benefit from IPC team expertise.
Organizations that shift discussions from "Are we compliant?" to "What is the actual patient risk?" create more meaningful and effective responses to contamination concerns.